Accretion Nutraveda Share Price & Earnings Call Analysis
₹325.00+1.23% today
- Market cap
- ₹235 Cr
- P/E
- 31.72
- ROE
- 25.02%
- PEG
- 0.19
- Price to sales
- 4.81
- Debt to equity
- 0.20
- EBITDA margin
- 19.74%
- Net profit margin
- 15.09%
- Promoter holding
- 73.48%
- Sales (last year)
- ₹49 Cr
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Financials of Accretion Nutraveda
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Accretion Nutraveda
Quarterly Results
Quarter-by-quarter operating performance
No quarterly results data available for this company yet.
Financials of Accretion Nutraveda
Profit & Loss
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 2.89 | 5.01 | 16.00 | 33.60 |
| Expenses + | 2.27 | 3.78 | 12.28 | 26.71 |
| Operating Profit | 0.62 | 1.23 | 3.72 | 6.89 |
| OPM % | 21.45% | 24.55% | 23.25% | 20.51% |
| Other Income + | 0.17 | 0.19 | 0.05 | 0.11 |
| Interest | 0.19 | 0.24 | 0.35 | 0.53 |
| Depreciation | 0.31 | 0.26 | 0.24 | 0.26 |
| Profit before tax | 0.29 | 0.92 | 3.18 | 6.21 |
| Tax % | 3.45% | 9.78% | 17.92% | 18.36% |
| Net Profit + | 0.28 | 0.82 | 2.61 | 5.07 |
| EPS in Rs | 7.78 | 22.78 | 53.59 | 7.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Accretion Nutraveda
Balance Sheet
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.36 | 0.36 | 0.49 | 7.24 |
| Reserves | -0.10 | 0.72 | 4.86 | 28.23 |
| Borrowings + | 1.97 | 2.17 | 3.86 | 4.23 |
| Other Liabilities + | 1.83 | 1.39 | 1.65 | 2.09 |
| Total Liabilities | 4.06 | 4.64 | 10.86 | 41.79 |
| Fixed Assets + | 1.49 | 1.28 | 2.02 | 1.66 |
| CWIP | 0.00 | 0.10 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets + | 2.57 | 3.26 | 8.84 | 40.13 |
| Total Assets | 4.06 | 4.64 | 10.86 | 41.79 |
Financials of Accretion Nutraveda
Cash Flows
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 0.68 | 0.23 | -2.21 | -23.92 |
| Cash from Investing Activity + | -0.01 | -0.16 | -0.87 | -0.08 |
| Cash from Financing Activity + | -0.63 | -0.04 | 2.98 | 25.27 |
| Net Cash Flow | 0.04 | 0.03 | -0.10 | 1.26 |
| Free Cash Flow | 0.67 | 0.07 | -3.08 | -24.00 |
| CFO/OP | 110% | 27% | -45% | -331% |
Financials of Accretion Nutraveda
Ratios
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 101.04 | 18.21 | 74.60 | 88.10 |
| Inventory Days | 279.12 | 303.74 | 158.50 | 136.10 |
| Days Payable | 354.26 | 113.58 | 30.73 | 13.63 |
| Cash Conversion Cycle | 25.89 | 208.37 | 202.36 | 210.57 |
| Working Capital Days | 8.84 | 7.29 | 111.32 | 352.07 |
| ROCE % | 42.34% | 56.66% | 27.56% |